The use of BRM-activated killer cells in adoptive immunotherapy: A pilot study with nine advanced cancer patients

Biotherapy

Volumn 11, Issue 4, 1998, Pages 241-253

  Ebina, Takusaburo ^a,b,c   Fujimiya, Yoshiaki ^a   Yamaguchi, Tomohiro ^a   Ogama, Naoko ^a   Sasaki, Hiroko ^a   Isono, Noriko ^a   Suzuki, Youichi ^a   Katakura, Ryuichi ^a   Tanaka, Kazuya ^a   Nagata, Kinya ^a   Takano, Shoichi ^a   Tamura, Keiji ^a   Uno, Kazuko ^a   Kishida, Tsunataro ^a  

^a MIYAGI CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b BML   (Japan)

^c Louis Pasteur Center for Medical Research   (Japan)

Author keywords

Adoptive immunotherapy; Biological response modifier, T cells; Immunosuppressive acidic protein; NK cells

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; GAMMA INTERFERON; IMMUNOSUPPRESSIVE ACID PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HUMAN; LYMPHOKINE ACTIVATED KILLER CELL; MALE; PATIENT CODING; PRIORITY JOURNAL; SURVIVAL TIME; TERMINALLY ILL PATIENT;

ADULT; AGED; BIOLOGICAL RESPONSE MODIFIERS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTERFERON-ALPHA; INTERLEUKIN-2; KILLER CELLS; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS; PILOT PROJECTS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032412291     PISSN: 0921299X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008047628284     Document Type: Article

References (26)

1. Lorish CD, Maisiak R. The Face Scale: a brief, nonverbal method for assessing patient mood. Arthritis and Rheumatism 1986:29:906-9.
2. Rosenberg SA. An immunotherapy of cancer using interleukin-2. Immunology Today 1988; 9: 58-62.
3. Fisher B, Packard BS, Read EJ, Carrasquillo JA, Carter CS, Topalian SL, Yang JC, Yolles P, Larson SM, Rosenberg SA. Tumor localization of adoptively transferred indium- 111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 1989; 7: 250-61.
4. Belldegrun A, Kasid A, Uppenkamp M, Topalian SL, Rosenberg SA. Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy. J Immunol 1989; 142: 4520-6.
5. loannides CG, Freedman RS, Platsoucas CD, Rashed S, Kirn YP. Cytotoxic T cell clones isolated from ovarian tumorinfiltrating lymphocytes recognize multiple antigenic epitopes on autologus tumor cells. J Immunol 1991; 146: 1700-7.
6. Maeda N, Hamasato S, Miyazawa H, Takata M, Yamamoto H, Fujimoto S. Augmentation of human cytotoxic T lymphocytes against autologous tumor by a factor released from human monocytic leukemia cell line. Jpn J Cancer Res 1989; 80: 5.375.
7. Karnofsky DA, Abelmann WH, Graver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948; 1: 634-56.
8. Haas W, Pereira P, Tonegawa S. y/S cells. Annu Rev Immunol 1993; 11:673-86.
9. Brenner MB, McLean J. Dialynas DP. Strominger JL, Smith JA, Owen FL, Seidman JG, Ip S, Rosen F, Krangel MS. Identification of a putative second T-cell receptor. Nature 1986; 322: 145-59.
10. Mombaerts P, Mizoguchi E, Ljunggren H-G, lacomini J, Ishikawa H, Wang L, Grusby MJ, Glimcher LH, Winn HJ, Bhan AK, Tonegawa S. Peripheral lymphoid development and function in TCR mutant mice. Int Immunol 1994; 6: 1061-70.
11. Fujimiya Y, Suzuki Y, Katakura R. Miyagi T, Yamaguchi T, Yoshimoto T, Ebina T. In vitro interleukin 12 activation of peripheral blood CD3+CD56+ and CD3+CD56" y5 T cells from glioblastoma patients. Clin Cancer Res 1997; 3: 633-43.
12. Nauinc B. Nonslad U, Steinkjer B, Funderud S, Smeland E. Espevik T. Immunomagnetic isolation of NK and LAK cells. J Immunological Methods 19%; 136: 1-9.
13. Yamaguchi T. Fujimiya Y. Suzuki Y. Katakura R, Ehina T. A simple method for the propagation and purification of γδT cells from the peripheral blood of glioblastoma patients using solid-phase anti-CD3 antibody and soluble IL-2. J Immunological Methods 1997; 205: 19-28.
14. Tamura K, Shibata Y, Matsuda Y, Lshida N. Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients. Cancer Research 1981; 41: 3244-52.
15. Hansen S. Iversen J, Lihme A. Bog-Hanse L. Acute phase reaction, heterogeneity, and microheterogeneity of serum proteins as nonspecific tumor markers in lung cancer. Cancer 1987:60: 1630-5.
16. Picker LJ. Shingh MK. Zdraveski Z, Treer JR, Waldrop SL. Bergstressor PR, Muino VC. Direct demonstration of cytokine synthesis heterogeneity among human menory/effector T cell by flow cytometry. Blood 1995; 86: 1408-19.
17. Sekine T. Shiraiwa H. Yamazaki T, Tobisu K, Kakizoe T. A feasible method for expansion of peripheral blood lymphocytes by culture with immobilized anti-CD3 monoclonal antibody and interleukin-2 for use in adoptive immunotherapy of cancer patients. Biomed Pharmacother 1993; 47: 73-8.
18. Ochoa AC. Hasz DE, Rezonzew R, Anderson PM. Bach FH. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: Identification and isolation of effector subsets. Cancer Res 1989: 49: 963-8.
19. Shibata Y. Tamura K. Ishida N. In vim analysis of the suppressive effects of immunosuppressive acidic protein, a type of alfa-1 acid glycoprotein, in connection with its high level in tumor-bearing mice. Cancer Res 1983: 43: 2889-96.
20. Ebina T. Murata K, Tamura K. Antitumor effect of intratumoral administration of biological response modifiers: Induction of immunosuppressive acidic protein, a type of a I-acid glycoprotein. in mice. Jpn J Cancer Res 1994; 85: 93-100.
21. Agneray J. Glycan microheterogeneity forms of alpha 1-acid glycoprotein (AGP). In: Alpha 1-Acid Glycoprotein: Genetics. Biochemistry. Physiological Functions, and Pharmacology. New York: Alan R. Liss. Inc.. 1989; 47-65.
22. Yoshimura A, Niitani H, et al. Combined effects of PSK with chemotherapy in the treatment of adenocarcinoma of the lung, assessment of quality of life (QOL). Biotherapy 1992: 6: 2567 (Japanese with English abstract).
23. Takeuchi K. Sato N. Kasahara H. Funayama N. Nagafuchi A, Yonemura S. Tsukita S. Tsukita S. Perturbation of cell adhesion and microbilli formation by antiscnse oligonucleotides to ERM family members. J Cell Biol. 1994: 125: 1371-84.
24. Rüegg C. Yilmaz A. Bieler G, Bamat J. Caubert P. Lejeune FJ. Evidence for the involvement of endothelial cell integrin αVβ3 by TNFand IFN-J. Nature Med. 1998: 4: 408-14.
25. Saito M. Seki S. Hashimoto W. Ogasawara K. Kobayashi T. Kumagai K. Matsuno S, Takeda K. Cytotoxic γδ or αβ T cells with a natural killer cell marker. CD56. induced from human peripheral blood lymphocytes by a combination of II.-12 and IL-2. J Immunol 1996: 157: 3886-92.
26. Antel JP, McCreu E, Ladiwala U. Qim Y. Becher B. NonMHC-restricted cell-mediated lysis of human oligodendrocytes in vitro: relation with CD56 expression. J. Immunol. 1998: 160: 1606-11.